Johnson & Johnson is now the third company with an FDA-approved PFA system in its portfolio, joining Medtronic and Boston Scientific. Varipulse previously gained CE mark approval in February.
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
- Clinical
- Management
- Technology
- Videos
- Conferences
- Custom Content
- Experience Stories
- Webinars & Videos
|Custom Content - Subscribe
![Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-08/screenshot_2024-08-12_at_11.35.13_am.png?itok=GxbuOU6H)
